Takeda Pharmaceutical has partnered with Fujifilm for the development of regenerative medicine therapies to treat heart failure.

Under the collaboration, Takeda will use cardiomyocytes that would be derived from iPSC at Fujifilm’s subsidiary Cellular Dynamics International in the US.

The alliance will see a combination of Fujifilm’s iPSC-related and engineering technologies expertise with Takeda’s iPSC technology capabilities.

The Center for iPS Cell Research and Application (CiRA) at Kyoto University will additionally support these efforts for regenerative medicine development through collaborative research and expertise in pre-clinical and clinical studies for making safe and effective drugs.

Fujifilm Regenerative Medicine division general manager Aiichiro Hiruma said: “In addition to establishing new treatment methods for patients with heart disease, Fujifilm and Takeda will contribute to the elevation of regenerative medication business to the industrial stage by applying our engineering technologies to manufacture high-quality cells safely and efficiently.”

“Fujifilm has impressive capabilities in high-quality cell manufacturing technology, an innovative area with significant treatment potential.”

Under the contract signed by the firms, Takeda holds an option to first negotiate a joint and global commercialisation of regenerative medicine products made using iPSC-derived cardiac cells.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Fujifilm is set to receive an upfront amount from Takeda, while both firms will investigate the safety and efficacy of the potential regenerative medicine therapies.

Takeda Regenerative Medicine Unit global head Seigo Izumo said: “Fujifilm has impressive capabilities in high-quality cell manufacturing technology, an innovative area with significant treatment potential.

“This collaboration allows us to leverage the strengths of both organisations with the goal of achieving meaningful, life-changing benefits for patients.”